CQN-FEELM
23.5.2023 04:44:27 CEST | Business Wire | Press release
Third paragraph, first sentence of the release dated May 17, 2023 should read: FEELM has made notable achievements in the closed pod system category, with around 3.5 billion pods sold to more than 50 countries since 2018. (instead of FEELM has made notable achievements in the closed pod system category, with around 3.5 million pods sold to more than 50 countries since 2018.)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516006108/en/
(Graphic: Business Wire)
The updated release reads:
FEELM Shares the Honor With Clients at This Year’s Vapouround Awards, Winning Across Four Categories
FEELM, the world’s leading closed system solution provider, belonging to SMOORE – a global leader in atomisation technology solutions – recently shone at the Vapouround 2023 annual awards ceremony in Birmingham last Friday, winning the Outstanding Contribution to the Vape Industry, and Best Manufacturer. Its client KIWI Go and DejaVoo Cyber also share the honor and won the first and second place of the “Best Disposable” categories respectively.
The Vapouround Awards are one of the most prestigious and authoritative annual awards for the global vaping industry. All winning brands are selected by a panel of professional judges and represent the outstanding performance of the past year in various segments of the industry. FEELM is not new to winning in the Vapouround Awards, with the brand having been awarded Industry Leader and Best Innovation in 2020.
FEELM has made notable achievements in the closed pod system category, with around 3.5 billion pods sold to more than 50 countries since 2018. Its disposable ceramic coil technologies have also already been launched in key markets including France, the UK, and Belgium, and will soon be available more widely in more countries.
FEELM has been dedicated to embracing innovations with the aim of taking the industry standard to new heights. While most of the 2ml e-liquid disposable products provide only 600 puffs, FEELM Max solutions can now deliver 800 puffs, all whilst remaining TPD-compliant.
At the Birmingham Vaper Expo, on the Saturday at its launch event, FEELM unveiled its new innovative disposable solution, FEELM Max, with the advanced heating technology of its S1 ceramic coil. FEELM Max offers more puffs, greater taste consistency, and a fully visible mouthpiece to measure e-liquid, making it the best disposable available whilst still ensuring regulatory compliance with the Tobacco and Related Products Regulations (TRPR) in the UK and the Tobacco Products Directive (TPD) in the EU.
FEELM Max is now available in markets including the UK, Italy and Germany, and have been well-received by consumers, who have said that it feels silkier and smoother than other products.
We look forward to continuing to bring our FEELM Max technology to more consumers, whilst ensuring that our solutions are always compliant with the regulatory requirements where they are sold.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516006108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom